ERYTECH announces enrollment of first patient in Phase II study of eryaspase in pancreatic cancer

  • Post author:
  • Post category:Newsroom

ERYTECH announces the enrollment of the first patient in its Phase II study with eryaspase in second line treatment of patients affected by pancreatic cancer.

Menu